Archives

  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • DiscoveryProbe FDA-approved Drug Library: Unlocking High-...

    2025-11-17

    DiscoveryProbe FDA-approved Drug Library: Unlocking High-Throughput Drug Repositioning

    Setup and Principle: Enabling Translational Discovery Through Ready-to-Use Compound Diversity

    The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) by APExBIO stands as a transformative resource for biomedical research, featuring 2,320 pre-dissolved, clinically vetted compounds spanning a broad mechanistic spectrum. Each molecule is pre-approved by major regulatory agencies (FDA, EMA, HMA, CFDA, PMDA) or listed in recognized pharmacopeias, ensuring translational relevance and safety profiles that accelerate bench-to-bedside workflows. With this FDA-approved bioactive compound library, investigators gain immediate access to receptor agonists/antagonists, enzyme inhibitors, ion channel modulators, and signal pathway regulators—laying a robust foundation for high-throughput screening drug library assays and high-content screening compound collection studies.

    The library’s unique value lies in its ability to facilitate drug repositioning screening and pharmacological target identification, empowering researchers to uncover novel indications for established drugs or to elucidate new pathways in disease models. Compounds are supplied as stable 10 mM DMSO solutions in flexible plate or tube formats (96-well microplates, deep well plates, 2D barcoded tubes), compatible with automated liquid handling and high-throughput platforms. Storage at -20°C (12 months) or -80°C (24 months) preserves compound integrity, while shipping flexibility (blue ice or room temperature) minimizes logistical barriers.

    Step-by-Step Workflow: Streamlined Protocols for Translational Success

    1. Plate Preparation and Compound Handling

    • Thawing: Remove DiscoveryProbe™ plates/tubes from -20°C or -80°C storage and thaw on ice to preserve compound stability.
    • Mixing: Gently vortex or pipette to ensure homogeneity of each 10 mM DMSO solution. Avoid excessive agitation to reduce DMSO evaporation and maintain molarity.
    • Aliquoting: Use low-retention tips and DMSO-compatible reservoirs to minimize compound loss and cross-contamination.

    2. Assay Setup

    • Seeding: Plate target cells (e.g., C2C12 myoblasts, cancer cell lines, primary neurons) in 96- or 384-well plates at optimal densities for your assay. For example, 5,000–10,000 cells/well for viability or transcriptional reporter assays.
    • Dosing: Using automated pipetting, transfer compounds to assay plates at desired final concentrations (typically 0.1–50 μM). Maintain DMSO <1% v/v to avoid solvent toxicity.
    • Controls: Include positive and negative controls on each plate; use DMSO-only wells to normalize for vehicle effects.

    3. Endpoint Readout

    • High-Throughput Screening (HTS): For cell viability, proliferation, or cytotoxicity, employ luminescence-, fluorescence-, or absorbance-based readouts (e.g., CellTiter-Glo, resazurin, or MTT).
    • High-Content Screening (HCS): Use automated imaging and machine learning–driven phenotypic analysis to extract multiplexed data on morphology, signaling, or differentiation markers.
    • Data Analysis: Normalize signals, calculate Z'-factors, and flag hit compounds for follow-up validation. The robust plate-to-plate consistency of the DiscoveryProbe™ library supports statistical rigor (Z'-factor >0.7 in published assays[1]).

    Advanced Applications and Comparative Advantages

    1. Drug Repositioning in Muscle Disease: Case Study in Sarcopenia

    A landmark study (Park et al., 2025) illustrates the translational power of the DiscoveryProbe FDA-approved Drug Library. Researchers screened the library using a PHF20-induced YY1 promoter assay in C2C12 myoblasts, seeking compounds that could counteract muscle atrophy. Sulfasalazine, originally indicated for inflammatory bowel disease, emerged as a potent inhibitor of PHF20-induced YY1 transcription (IC50 = 24 μM). This blockade promoted muscle-specific gene expression and enhanced muscle strength in mouse atrophy models. Notably, retrospective clinical data revealed that IBD patients treated with sulfasalazine exhibited increased muscle mass (higher total psoas index), suggesting real-world repositioning potential.

    This workflow exemplifies how a high-throughput screening drug library can bridge cell-based assays, animal models, and clinical informatics—accelerating the repurposing of FDA-approved agents for unmet indications such as sarcopenia, where no regulatory-approved therapies currently exist.

    2. Oncology and Neurodegenerative Disease Discovery

    The DiscoveryProbe™ library’s breadth enhances cancer research drug screening and neurodegenerative disease drug discovery. Its inclusion of canonical agents (e.g., doxorubicin, metformin, atorvastatin) alongside diverse mechanistic classes enables:

    • Signal pathway regulation: Systematic exploration of kinase, phosphatase, or receptor pathway modulators in tumor or neuronal models.
    • Enzyme inhibitor screening: Rapid identification of compounds modulating disease-relevant enzymes (e.g., HDACs, proteases, kinases).
    • Resistance mechanism profiling: Parallel assessment of candidate drugs against established resistant cell lines.
    Supported by interlinked resources, this review complements the present workflow by detailing how the DiscoveryProbe FDA-approved Drug Library accelerates pharmacological target identification across oncology and neurobiology, while another analysis extends these insights with protocol adaptations for translational mechanistic discovery.


    3. Workflow Reliability and Automation

    As detailed in practical lab scenarios, the pre-dissolved, format-flexible nature of the DiscoveryProbe™ collection reduces hands-on time by up to 40% compared to traditional solid-form libraries. Compatibility with automated liquid handling (robotic pipettors, plate stackers) and high-content imaging platforms minimizes error, maximizes throughput, and supports large-scale screening endeavors in both academic and industrial settings.

    Troubleshooting and Optimization Tips

    • Solubility & Precipitation: All compounds are provided as DMSO solutions; however, upon dilution into aqueous buffers, some hydrophobic agents may precipitate. Pre-warm plates to 37°C and vortex briefly after dilution. For persistent precipitation, increase DMSO to 1% v/v (ensure cell tolerance) or use gentle sonication.
    • Edge Effects in Microplates: To mitigate evaporation or temperature gradients, fill outer wells with buffer or DMSO and use internal wells for assays. Plate sealing during incubations further enhances consistency.
    • Compound Degradation: Limit freeze–thaw cycles by aliquoting master stocks. If a drop in activity is observed, compare with a fresh aliquot to confirm compound integrity.
    • Assay Interference: Some compounds (e.g., colored or autofluorescent drugs) may interfere with readouts. Include a no-cell/no-substrate control for each compound to identify and correct for intrinsic signal.
    • Z'-Factor Monitoring: Routinely calculate Z'-factors (aim for >0.5) to monitor assay quality. Outlier plates should be flagged, and hits from those plates re-tested.

    Future Outlook: Expanding Horizons in Drug Discovery and Precision Medicine

    The DiscoveryProbe FDA-approved Drug Library is a critical enabler for next-generation screening paradigms, particularly as precision medicine and multi-omics approaches reshape therapeutic discovery. Its clinically aligned composition and mechanistic diversity support:

    • AI-driven hit prioritization and structure–activity relationship (SAR) modeling.
    • Integration with CRISPR or RNAi screens to map genetic–chemical interactions.
    • Rapid pivoting to emerging disease indications, as exemplified by the repositioning of sulfasalazine for sarcopenia management (Park et al., 2025).
    APExBIO’s commitment to quality, format flexibility, and translational support positions the DiscoveryProbe™ FDA-approved Drug Library as a trusted foundation for both fundamental research and clinical innovation. As biological complexity and therapeutic needs evolve, this high-content screening compound collection will remain at the forefront of drug discovery, enabling researchers worldwide to accelerate discoveries from the bench to the bedside.


    References:
    [1] DiscoveryProbe™ FDA-approved Drug Library: High-Content S...
    [2] Therapeutic potential of sulfasalazine for sarcopenia: Insights from mouse models and clinical data